MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change - Vemuri, P; Wiste, H J; Weigand, S D; Shaw, L M; Trojanowski, J Q; Weiner, M W; Knopman, D S; Petersen, R C; Jack, Jr, C R (Neurology, 2009)
Keywords: Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - pathology; Alzheimer Disease - physiopathology; Amyloid beta-Peptides - analysis; Amyloid beta-Peptides - cerebrospinal fluid; Biomarkers - analysis; Biomarkers - cerebrospinal fluid; Brain - metabolism; Brain - pathology; Brain - physiopathology; Cognition Disorders - cerebrospinal fluid; Cognition Disorders - pathology; Cognition Disorders - physiopathology; Cohort Studies; Cross-Sectional Studies; Diagnosis, Differential; Disease Progression; Female; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Memory Disorders - cerebrospinal fluid; Memory Disorders - pathology; Memory Disorders - physiopathology; Middle Aged; Neuropsychological Tests; Peptide Fragments - analysis; Peptide Fragments - cerebrospinal fluid; Predictive Value of Tests; Prognosis; Proportional Hazards Models; tau Proteins - analysis; tau Proteins - cerebrospinal fluid